OpenNeedle Ask your own

Question explored with the scientific record

Conversation so far

  1. 1 risk of myocarditis pericarditis after covid vaccine
  2. 2 highest risk of myocarditis pericarditis after covid vaccine

Answered on this page ↓

highest risk of myocarditis pericarditis after covid vaccine

Nov 21, 2026 · 10 sources used · OpenNeedle synthesis
The highest risk is in males 12-29, after the second mRNA dose, in the first week, and Moderna is the riskier product.

The age and sex signal is consistent across countries. Young males 16-29 carry the highest rate, mostly after dose two [1][2][3]. A Danish national cohort found Moderna carried a hazard ratio of 5.24 versus unvaccinated in ages 12-39 [1]. An English self-controlled analysis found the highest relative incidence after a second Moderna dose in 16-39 year olds, far above Pfizer's second dose [5]. A Korean pharmacovigilance study put the peak in males 18-24 after dose two [7].

Group / exposureRisk figure
Males 16-29, Pfizer (Israel)10.69 per 100,000 [1][4]
Males 12-17, dose 2 (meta-analysis)15.7 per 100,000 [6]
US boys 12-15, dose 2162 per million [10]
US boys 16-17, dose 293 per million [10]
Moderna vs unvaccinated, 12-39HR 5.24 [1]
Moderna dose 2 vs baseline, 16-39RI 56.48 [5]

The timing is tight. Symptoms cluster 2-5 days after the second dose [3][8][9], and the English data put the elevated window at 0-6 days post-vaccination [5]. Pericarditis is a smaller signal than myocarditis, with the clearest bump after a second Moderna dose in 16-39 year olds [5].

The VAERS-derived figures [10] rest on voluntary reports, which undercount and can overcount. The cohort and self-controlled designs [1][5] are stronger. None of this is randomized.

My call: if you want the single highest-risk profile, it is a male in his late teens or twenties getting a second Moderna dose, with symptoms most likely in the first week. Confidence: moderate.

Keep digging

Sources used 10

  1. The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis Netherlands Heart Journal (2022) narrative review Strong

    COVID-19 mRNA vaccination clearly outweighs the rare risk of myocarditis and pericarditis; incidence is about 1-4 per 100,000, mainly in young males after the second dose, and COVID-19 itself poses a much larger myocarditis risk.

    DOI: 10.1007/s12471-022-01677-9
  2. Disentangling a Thorny Issue: Myocarditis and Pericarditis Post COVID-19 and Following mRNA COVID-19 Vaccines Pharmaceuticals (2022) Thin

    This pharmacovigilance study analyzes the incidence of myocarditis and pericarditis reported in the Vaccine Adverse Events Reporting System (VAERS) following mRNA COVID-19 vaccinations, revealing a higher incidence in young males after the second dose, but a lower risk compared …

    DOI: 10.3390/ph15050525
  3. Incidence, Clinical Presentation, and Management of Myocarditis following mRNA-Based Covid-19 Vaccines: A Brief Report Cardiology (2022) narrative review Mixed

    Myocarditis after mRNA Covid-19 vaccines is rare, most common in younger men after the second dose, usually mild and self-limiting, with the benefit of vaccination outweighing the risk.

    DOI: 10.1159/000522216
  4. Acute myocarditis caused by COVID-19 disease and following COVID-19 vaccination Open Heart (2022) narrative review Strong

    This narrative review summarizes evidence that COVID-19 and mRNA COVID-19 vaccination can cause rare myocarditis, most common in younger males after second dose, with favourable short-term course and benefit-risk favouring vaccination.

    DOI: 10.1136/openhrt-2021-001957
  5. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England PLOS Medicine (2023) primary study Strong

    In England, mRNA COVID-19 vaccine doses, especially second doses in males aged 16-39, elevated short-term risk of myocarditis admission; booster risks were lower and prior infection did not increase vaccine risk, but SARS-CoV-2 infection itself carried elevated myocarditis risk.

    DOI: 10.1371/journal.pmed.1004245
  6. Myocarditis in Adolescents (12-17 years) Associated with the Pfizer-BioNTech (BNT162b2) Vaccine: A Systematic Review and Meta-analysis American Journal of Health, Medicine and Nursing Practice (2023) meta-analysis Strong

    In a meta-analysis of four observational studies, BNT162b2-associated myocarditis in adolescents was rare, with male predominance and higher incidence after the second dose.

    DOI: 10.47672/ajhmn.1387
  7. COVID-19 Vaccination-Related Myocarditis: What We Learned From Our Experience and What We Need to Do in The Future Korean Circulation Journal (2024) Thin

    This review examines the incidence, risk factors, clinical presentation, pathogenesis, management strategies, and outcomes of vaccine-related myocarditis (VRM) associated with COVID-19 mRNA vaccines, highlighting the need for continued surveillance and research to mitigate risks…

    DOI: 10.4070/kcj.2024.0065
  8. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review BMJ (2022) systematic review Strong

    This living systematic review found that myocarditis after mRNA COVID-19 vaccination occurs most frequently in male adolescents and young adults, with moderate-certainty evidence that Moderna is associated with higher incidence than Pfizer in 18-29 year olds and low-certainty ev…

    DOI: 10.1136/bmj-2021-069445
  9. COVID-19 mRNA vaccine-induced myocarditis Demiroglu Science University Florence Nightingale Journal of Medicine (2022) narrative review Strong

    This narrative review synthesizes the classification, diagnostic methods (including the revised Lake Louise Criteria for cardiac MRI), and management of myocarditis, with a specific focus on COVID-19 mRNA vaccine-associated myocarditis, which predominantly affects males and typi…

    DOI: 10.5606/fng.btd.2022.115
  10. BNT162b2 Vaccine‐Associated Myo/Pericarditis in Adolescents: A Stratified Risk‐Benefit Analysis European Journal of Clinical Investigation (2022) primary study Strong

    VAERS-derived myo/pericarditis incidence after BNT162b2 dose two was 162.2/million in US boys 12-15 and 93.0/million in boys 16-17; stratified risk-benefit modeling found two doses uniformly favorable only in nonimmune girls with comorbidities, favoring individualized pediatric …

    DOI: 10.1111/eci.13759

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question →